Want to see AVIR full AI Analyst Report?
AVIR Stock Chart & Stats
$5.74
$0.04(1.19%)
At close: 4:00 PM EST
$5.74
$0.04(1.19%)
Day’s Range― - ―
52-Week Range$2.78 - $6.45
Previous CloseN/A
Volume180.19K
Average Volume (3M)331.21K
Market Cap
$392.93M
Enterprise Value$267.83M
Total Cash (Recent Filing)$256.01M
Total Debt (Recent Filing)$634.00K
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Aug 06, 2026EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.11
Shares Outstanding80,027,100
10 Day Avg. Volume266,515
30 Day Avg. Volume331,208
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)1.06
Price to Sales (P/S)0.00
P/FCF Ratio-2.20
Enterprise Value/Market Cap0.68
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.57
Enterprise Value/Ebitda-1.49
Forecast
1Y Price Target
$6.00Price Target Upside4.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.92
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage & Cash RunwayA large cash balance and minimal debt materially reduce near-term financing pressure, enabling completion of Phase 3 and initial HEV studies while supporting manufacturing readiness. This balance-sheet strength preserves operational optionality through key clinical inflection points before new capital is needed.
Robust Phase 3 Enrollment & DesignCompleted enrollment and statistically rigorous trial designs reduce execution and enrollment risk and increase the likelihood of timely, interpretable top-line SVR24 readouts. Well-powered, predefined endpoints improve the probability of regulatory acceptance and support label claims, strengthening the path to commercialization.
Manufacturing & Commercial ReadinessHaving commercial-scale manufacturing, low expected COGS and packaging in place shortens time-to-market and reduces execution risk at launch. When paired with concentrated prescriber patterns, this supports a capital-efficient commercial model and better margin leverage versus businesses that must build supply chains post-approval.
Bears Say
No Revenue & Sustained LossesAbsence of recurring commercial revenue and significant, sustained cash burn make the business model dependent on financing, partnerships or milestone payments. Continued losses and declining equity/assets erode financial flexibility and increase reliance on successful clinical outcomes to generate future cash flow.
Limited Cash Runway Beyond 2027While current cash covers Phase 3 completion and near-term programs, the runway does not extend comfortably into commercialization and market access phases. The need for additional financing could dilute stakeholders, divert management focus, or delay launch activities if capital terms are unfavorable.
Regulatory Complexity Across RegionsDifferent primary analysis populations for FDA and EMA complicate pooled interpretation and regulatory submissions, increasing the chance of divergent outcomes, extra analyses or extended review timelines. This structural complexity raises approval and labeling uncertainty across key markets.
Atea Pharmaceuticals News
AVIR FAQ
What was Atea Pharmaceuticals, Inc.’s price range in the past 12 months?
Atea Pharmaceuticals, Inc. lowest stock price was $2.78 and its highest was $6.45 in the past 12 months.
What is Atea Pharmaceuticals, Inc.’s market cap?
Atea Pharmaceuticals, Inc.’s market cap is $392.93M.
When is Atea Pharmaceuticals, Inc.’s upcoming earnings report date?
Atea Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 26 days.
How were Atea Pharmaceuticals, Inc.’s earnings last quarter?
Atea Pharmaceuticals, Inc. released its earnings results on May 12, 2026. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.555 by -$0.015.
Is Atea Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Atea Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Atea Pharmaceuticals, Inc. pay dividends?
Atea Pharmaceuticals, Inc. does not currently pay dividends.
What is Atea Pharmaceuticals, Inc.’s EPS estimate?
Atea Pharmaceuticals, Inc.’s EPS estimate is -0.56.
How many shares outstanding does Atea Pharmaceuticals, Inc. have?
Atea Pharmaceuticals, Inc. has 80,027,100 shares outstanding.
What happened to Atea Pharmaceuticals, Inc.’s price movement after its last earnings report?
Atea Pharmaceuticals, Inc. reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.555. Following the earnings report the stock price went down -16.909%.
Which hedge fund is a major shareholder of Atea Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in AVIR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atea Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (4.53% Upside)
$6.00 (4.53% Upside)
Blogger Sentiment
Bullish
AVIR Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 12.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $25.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.37%
12-Months-Change
Fundamentals
Return on Equity
-57.01%
Trailing 12-Months
Asset Growth
-39.30%
Trailing 12-Months
Company Description
Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
AVIR Company Deck
AVIR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a largely positive outlook driven by strong operational progress: completed enrollment for the U.S. Phase 3 (C‑BEYOND), near‑complete enrollment ex‑U.S. (C‑FORWARD), a well‑powered trial design (90% power, 5% non‑inferiority), an advancing HEV program (CTA enabling studies done, FIH mid‑year), clear prescriber interest, manufacturing readiness, and $256M in cash with runway through 2027. Key risks include a limited cash runway beyond 2027, higher R&D spend, regulatory complexity (different primary analysis populations for FDA vs EMA), payer and market access uncertainties, and clinical/regulatory risk for the novel HEV program. On balance, operational milestones and program momentum outweigh the noted risks.View all AVIR earnings summariesAVIR Stock 12 Month Forecast
Average Price Target
$6.00
▲(4.53% Upside)
Technical Analysis
Ownership Overview
11.29% Insiders
16.76% Mutual Funds
0.02% Other Institutional Investors
60.42% Public Companies and
Individual Investors